The guidance for immunocompromised patients receiving Ronapreve, or casirivimab and imdevimab, is outlined in the Interim Clinical Commissioning Policy: Casirivimab and imdevimab for patients hospitalised due to COVID-19 which is available in an online only format. This policy states that hospitalised patients may be eligible for Ronapreve if they are:
- 12 to 49 years old and determined to be immunocompromised by multi-disciplinary team assessment, or
- 50 years old or over whether or not they are immunocompromised.
In either case, all eligible patients must also have COVID-19 infection confirmed by polymerase chain reaction test or where a multidisciplinary team has a high level of confidence that the clinical and/or radiological features suggest that COVID-19 is the most likely diagnosis, be hospitalised specifically for the management of acute symptoms and be negative for baseline serum anti-spike antibodies against COVID-19.
Immunocompromised patients will not be eligible for Ronapreve if they are children weighing less than 40 kilograms; they are children aged under 12 years old; they have known hypersensitivity reaction to the active substances or to any of the excipients of casirivimab and imdevimab listed in the Summary of Product Characteristics; or they have previously received treatment in hospital with casirivimab and imdevimab at the 2.4 gram (combined) dose or higher.
Interim Clinical Commissioning Policy (pdf, 339.2KB)